Travere Therapeutics (TVTX)

Company Profile

Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.

Company profile

Ticker

TVTX

Exchange

NASDAQ

Website

www..travere.com

CEO

Eric Dube

Incorporated

California

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

Former names

Desert Gateway, Inc., Retrophin, Inc.

SEC CIK

0001438533

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Travere Therapeutics Research Ltd • Travere Therapeutics US Holdings, LLC • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...

IRS number

262383102

TVTX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$30.67

Low target

$22.00

High target

$42.00

Latest filings (excl ownership)

View all

8-K

Travere Therapeutics Provides Corporate Update and 2023 Outlook

27 Oct 22

Travere Therapeutics Reports Third Quarter 2022 Financial Results

Registration of securities for employees

18 Aug 22

8-K/A

Departure of Directors or Certain Officers

4 Aug 22

Travere Therapeutics Reports Second Quarter 2022 Financial Results

Transcripts

View all

TVTX

Earnings call transcript

2022 Q3

28 Oct 22

TVTX

Earnings call transcript

2022 Q2

7 Aug 22

TVTX

Earnings call transcript

2022 Q1

8 May 22

TVTX

Earnings call transcript

2021 Q4

25 Feb 22

TVTX

Earnings call transcript

2021 Q3

29 Oct 21

TVTX

Earnings call transcript

2021 Q2

31 Jul 21

TVTX

Earnings call transcript

2021 Q1

9 May 21

TVTX

Earnings call transcript

2020 Q4

2 Mar 21

TVTX

Earnings call transcript

2020 Q3

8 Nov 20

TVTX

Earnings call transcript

2020 Q2

2 Aug 20

Latest ownership filings

View all

ADAGE CAPITAL PARTNERS GP, L.L.C.

28 Oct 22

Peter Heerma

6 Oct 22

Financial summary

Financial statements Chart TVTX financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	151.34 mm	151.34 mm	151.34 mm	151.34 mm	151.34 mm	151.34 mm
Cash burn (monthly)	9.47 mm	(no burn)	23.17 mm	22.00 mm	13.18 mm	13.21 mm
Cash used (since last report)	36.95 mm	n/a	90.38 mm	85.81 mm	51.39 mm	51.53 mm
Cash remaining	114.38 mm	n/a	60.96 mm	65.53 mm	99.95 mm	99.81 mm
Runway (months of cash)	12.1	n/a	2.6	3.0	7.6	7.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TVTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	171	171	–
Opened positions	24	21	+14.3%
Closed positions	24	24	–
Increased positions	62	55	+12.7%
Reduced positions	54	67	-19.4%

13F shares	Current	Prev Q	Change
Total value	1.71 bn	2.14 bn	-20.2%
Total shares	68.97 mm	72.26 mm	-4.5%
Total puts	99.10 k	78.20 k	+26.7%
Total calls	338.20 k	107.60 k	+214.3%
Total put/call ratio	0.3	0.7	-59.7%

Largest owners	Shares	Value	Change
Armistice Capital	5.84 mm	$143.80 mm	+9.7%
Ra Capital Management	4.92 mm	$121.30 mm	0.0%
BLK Blackrock	4.56 mm	$112.48 mm	+1.4%
Deep Track Capital	4.00 mm	$98.56 mm	+11.7%
JHG Janus Henderson	3.91 mm	$96.40 mm	-3.1%
Vanguard	3.38 mm	$83.32 mm	+1.5%
MCQEF Macquarie	3.31 mm	$81.59 mm	-9.8%
Baker Bros. Advisors	3.30 mm	$81.31 mm	0.0%
GS Goldman Sachs	2.55 mm	$62.93 mm	-2.2%
Adage Capital Partners GP, L.L.C.	2.35 mm	$57.90 mm	+20.5%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-3.61 mm	EXIT
VR Adviser	0.00	-1.71 mm	EXIT
Kynam Capital Management	416.73 k	-818.42 k	-66.3%
Armistice Capital	5.84 mm	+516.00 k	+9.7%
Orbimed Advisors	1.25 mm	+480.93 k	+62.3%
Perceptive Advisors	90.75 k	-479.34 k	-84.1%
Healthcare Of Ontario Pension Plan Trust Fund	756.00 k	+445.50 k	+143.5%
Finepoint Capital	1.03 mm	+444.58 k	+76.1%
Deep Track Capital	4.00 mm	+419.30 k	+11.7%
Millennium Management	599.00 k	+406.18 k	+210.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TVTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
25 Jan 23	Sandra Calvin	Common Stock	Sell	Dispose S	No	Yes	21.63	192	4.15 k	34,836
24 Jan 23	Rote William E.	Common Stock	Sell	Dispose S	No	Yes	21.5	2,062	44.33 k	42,376
24 Jan 23	Reed Elizabeth E	Common Stock	Sell	Dispose S	No	Yes	21.5	2,062	44.33 k	39,776
24 Jan 23	Eric M Dube	Common Stock	Sell	Dispose S	No	Yes	21.5	6,442	138.50 k	147,846
24 Jan 23	Christopher R. Cline	Common Stock	Sell	Dispose S	No	No	21.9044	852	18.66 k	32,871
24 Jan 23	Sandra Calvin	Common Stock	Sell	Dispose S	No	No	21.9044	905	19.82 k	35,028